|
1
|
Parekh N, Donohue JM, Men A, Corbelli J
and Jarlenski M: Cervical Cancer Screening Guideline Adherence
Before and After Guideline Changes in Pennsylvania Medicaid. Obstet
Gynecol. 129:66–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Machalek DA, Wark JD, Tabrizi SN, Hopper
JL, Bui M, Dite GS, Cornall AM, Pitts M, Gertig D, Erbas B, et al:
Genetic and environmental factors in invasive cervical cancer:
Design and methods of a classical twin study. Twin Res Hum Genet.
20:10–18. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sawaya GF and Smith-McCune K: Cervical
cancer screening. Obstet Gynecol. 127:459–467. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Knudson AG Jr: Overview: Genes that
predispose to cancer. Mutat Res. 247:185–190. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sandén C and Gullberg U: The DEK
oncoprotein and its emerging roles in gene regulation. Leukemia.
29:1632–1636. 2015.PubMed/NCBI
|
|
6
|
Deutzmann A, Ganz M, Schönenberger F,
Vervoorts J, Kappes F and Ferrando-May E: The human oncoprotein and
chromatin architectural factor DEK counteracts DNA replication
stress. Oncogene. 34:4270–4277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sandén C, Nilsson HJ and Gullberg U: The
DEK oncoprotein is upregulated by multiple leukemia-associated
fusion genes. Blood Cells Mol Dis. 54:284–285. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Qi D, Qi J, Mao Z, Li X, Zhang J,
Li J and Gao W: Significance of DEK overexpression for the
prognostic evaluation of non-small cell lung carcinoma. Oncol Rep.
35:155–162. 2016.PubMed/NCBI
|
|
9
|
Yi HC, Liu YL, You P, Pan JS, Zhou JY, Liu
ZJ and Zhang ZY: Overexpression of DEK gene is correlated with poor
prognosis in hepatocellular carcinoma. Mol Med Rep. 11:1318–1323.
2015.PubMed/NCBI
|
|
10
|
Wise-Draper TM, Morreale RJ, Morris TA,
Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP,
Wikenheiser-Brokamp KA, Lambert PF, et al: DEK proto-oncogene
expression interferes with the normal epithelial differentiation
program. Am J Pathol. 174:71–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martinez-Useros J, Rodriguez-Remirez M,
Borrero-Palacios A, Moreno I, Cebrian A, del Gomez Pulgar T, del
Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, et al: DEK is
a potential marker for aggressive phenotype and irinotecan-based
therapy response in metastatic colorectal cancer. BMC Cancer.
14:9652014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu HG, Scholten I, Gruss C and Knippers R:
The distribution of the DEK protein in mammalian chromatin. Biochem
Biophys Res Commun. 358:1008–1014. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sawatsubashi S, Murata T, Lim J, Fujiki R,
Ito S, Suzuki E, Tanabe M, Zhao Y, Kimura S, Fujiyama S, et al: A
histone chaperone, DEK, transcriptionally coactivates a nuclear
receptor. Genes Dev. 24:159–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu K, Feng T, Liu J, Zhong M and Zhang S:
Silencing of the DEK gene induces apoptosis and senescence in CaSki
cervical carcinoma cells via the up-regulation of NF-κB p65. Biosci
Rep. 32:323–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vinnedge Privette LM, McClaine R, Wagh PK,
Wikenheiser-Brokamp KA, Waltz SE and Wells SI: The human DEK
oncogene stimulates β-catenin signaling, invasion and mammosphere
formation in breast cancer. Oncogene. 30:2741–2752. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vinnedge Privette LM, Ho SM,
Wikenheiser-Brokamp KA and Wells SI: The DEK oncogene is a target
of steroid hormone receptor signaling in breast cancer. PLoS One.
7:e469852012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carro MS, Spiga FM, Quarto M, Di Ninni V,
Volorio S, Alcalay M and Müller H: DEK Expression is controlled by
E2F and deregulated in diverse tumor types. Cell Cycle.
5:1202–1207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Woodgett JR: Molecular cloning and
expression of glycogen synthase kinase-3/factor A. EMBO J.
9:2431–2438. 1990.PubMed/NCBI
|
|
19
|
Eldar-Finkelman H: Glycogen synthase
kinase 3: An emerging therapeutic target. Trends Mol Med.
8:126–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park CH, Lee BH, Ahn SG, Yoon JH and Oh
SH: Serine 9 and tyrosine 216 phosphorylation of GSK-3β
differentially regulates autophagy in acquired cadmium resistance.
Toxicol Sci. 135:380–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu Y, Gu X, Li R, Luo Q and Xu Y: Glycogen
synthase kinase-3β inhibition induces nuclear factor-κB-mediated
apoptosis in pediatric acute lymphocyte leukemia cells. J Exp Clin
Cancer Res. 29:1542010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He F, Chen H, Yang P, Wu Q, Zhang T, Wang
C, Wei J, Chen Z, Hu H, Li W, et al: Gankyrin sustains
PI3K/GSK-3β/β-catenin signal activation and promotes colorectal
cancer aggressiveness and progression. Oncotarget. 7:81156–81171.
2016.PubMed/NCBI
|
|
23
|
Hartigan JA, Xiong WC and Johnson GV:
Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2.
Biochem Biophys Res Commun. 284:485–489. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miyashita K, Nakada M, Shakoori A,
Ishigaki Y, Shimasaki T, Motoo Y, Kawakami K and Minamoto T: An
emerging strategy for cancer treatment targeting aberrant glycogen
synthase kinase 3 beta. Anticancer Agents Med Chem. 9:1114–1122.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cole A, Frame S and Cohen P: Further
evidence that the tyrosine phosphorylation of glycogen synthase
kinase-3 (GSK3) in mammalian cells is an autophosphorylation event.
Biochem J. 377:249–255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bhat RV, Shanley J, Correll MP, Fieles WE,
Keith RA, Scott CW and Lee CM: Regulation and localization of
tyrosine216 phosphorylation of glycogen synthase kinase-3beta in
cellular and animal models of neuronal degeneration. Proc Natl Acad
Sci USA. 97:11074–11079. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hsieh CH, Hsu HH, Shibu MA, Day CH, Bau
DT, Ho CC, Lin YM, Chen MC, Wang SH and Huang CY: Down-regulation
of β-catenin and the associated migration ability by Taiwanin C in
arecoline and 4-NQO-induced oral cancer cells via GSK-3β
activation. Mol Carcinog. 56:1055–1067. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu C, Dong T, Li R, Lu J, Wei X and Liu P:
Emodin inhibits epithelial to mesenchymal transition in epithelial
ovarian cancer cells by regulation of GSK-3β/β-catenin/ZEB1
signaling pathway. Oncol Rep. 35:2027–2034. 2016.PubMed/NCBI
|
|
29
|
Fu Y, Zheng S, An N, Athanasopoulos T,
Popplewell L, Liang A, Li K, Hu C and Zhu Y: β-catenin as a
potential key target for tumor suppression. Int J Cancer.
129:1541–1551. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gupta A, Verma A, Mishra AK, Wadhwa G,
Sharma SK and Jain CK: The Wnt pathway: Emerging anticancer
strategies. Recent Pat Endocr Metab Immune Drug Discov. 7:138–147.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nair RR, Solway J and Boyd DD: Expression
cloning identifies transgelin (SM22) as a novel repressor of 92-kDa
type IV collagenase (MMP-9) expression. J Biol Chem.
281:26424–26436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Varela AT, Simões AM, Teodoro JS, Duarte
FV, Gomes AP, Palmeira CM and Rolo AP: Indirubin-3′-oxime prevents
hepatic I/R damage by inhibiting GSK-3beta and mitochondrial
permeability transition. Mitochondrion. 10:456–463. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wilson KL, Cowart CJ, Rosen BL, Pulczinski
JC, Solari KD, Ory MG and Smith ML: Characteristics associated with
HPV diagnosis and perceived risk for cervical cancer among
unmarried, sexually active college women. J Cancer Educ. Nov
28–2016.(Epub ahead of print). View Article : Google Scholar
|
|
35
|
Liu S, Wang X, Sun F, Kong J, Li Z and Lin
Z: DEK overexpression is correlated with the clinical features of
breast cancer. Pathol Int. 62:176–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Datta A, Adelson ME, Mogilevkin Y,
Mordechai E, Sidi AA and Trama JP: Oncoprotein DEK as a tissue and
urinary biomarker for bladder cancer. BMC Cancer. 11:2342011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Domoto T, Pyko IV, Furuta T, Miyashita K,
Uehara M, Shimasaki T, Nakada M and Minamoto T: Glycogen synthase
kinase-3β is a pivotal mediator of cancer invasion and resistance
to therapy. Cancer Sci. 107:1363–1372. 2016. View Article : Google Scholar : PubMed/NCBI
|
